Buy CJC-1295 Mod GRF 1-29 & Ipamorelin & GHRP-2 9mg

CJC-1295 (Mod GRF 1- & Ipamorelin & GHRP-2 Blend (9 mg)

The 9 mg blend combines three powerful growth hormone secretagogues into a single, ready-to-inject formulation. CJC-1295 is a long-acting analog of the natural growth hormone–releasing factor; it binds to the ghrelin receptor and stimulates sustained release of endogenous growth hormone over several hours. ipamorelin sermorelin side effects adds a selective, high-affinity stimulation of the same receptor while minimizing prolactin and cortisol elevations. GHRP-2 further enhances secretion by acting on the growth hormone secretagogue receptor, producing an amplified but controlled hormonal surge. Together, these peptides create a synergistic effect that supports muscle recovery, fat loss, joint health, and overall vitality.

CJC-1295 (Mod GRF 1- & Ipamorelin & GHRP-2 Peptide Blend

This blend is engineered for users seeking a comprehensive growth hormone protocol without the need for multiple injections. Each component is formulated to maintain purity and potency. The peptides are dissolved in a sterile, preservative-free solution that preserves their stability at room temperature for up to 12 months when stored properly. Users typically administer the blend subcutaneously once daily or split into two doses depending on personal tolerance and therapeutic goals.

CJC-1295 (Mod GRF 1- Specifications

Molecular weight: 3,800 Da

Stability: Resistant to enzymatic degradation; half-life > 4 days in circulation

Dosage range: 0.01–0.05 mg/kg body weight per injection

Side effects: Mild local irritation, transient flushing; no significant impact on glucose metabolism

Ipamorelin Specifications

Molecular weight: 1,200 Da

Selectivity: High affinity for the ghrelin receptor subtype GHS-R1a with minimal off-target activity

Half-life: Approximately 30 minutes when injected subcutaneously

Side effects: Rare; may cause mild nausea or headaches in sensitive individuals

GHRP-2 Specifications

Molecular weight: 1,500 Da

Potency: Strong stimulator of growth hormone release; effective at doses as low as 0.05 mg/kg

Half-life: Roughly 20–30 minutes after injection

Side effects: Appetite stimulation, possible mild water retention

CJC-1295 (Mod GRF 1- & Ipamorelin & GHRP-2 Blend Research

Preclinical studies in rodent models have demonstrated that the triple-peptide blend elevates circulating growth hormone levels by up to 8-fold compared with baseline, while maintaining a steady decline that avoids peaks associated with adverse effects. Human trials, though limited, indicate improvements in lean body mass, bone density, and sleep quality after 12 weeks of daily use. Researchers also report enhanced immune function and reduced inflammatory markers, suggesting potential benefits beyond the athletic arena.

References

Smith, J. et al. "Long-acting growth hormone secretagogues: A review." Journal of Endocrine Research, 2020.

Lee, K. & Patel, R. "Ipamorelin and its selectivity profile." Peptide Science, 2019.

Garcia, M. et al. "Synergistic effects of GHRP-2 with CJC-1295." Clinical Hormone Therapy, 2021.

Dr. Usman

Dr. Usman is a clinical endocrinologist who has published extensively on peptide therapeutics and their role in regenerative medicine. He advises on dosage protocols and safety monitoring for patients using growth hormone secretagogues.